AgingResearch.NewsJoin free

Hesc-derived retinal pigment epithelium

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • 2 of 2 findings with company ties
  • Human trial1

Outcomes

2

Visual acuity

upin humans1

1 study

  1. Hesc-derived retinal pigment epithelium improves visual acuity in humans (from 21 ETDRS letters to 28).

    “vision also seemed to improve in the patient with dry age-related macular degeneration (from 21 ETDRS letters to 28).”

    Human trialdry age-related macular degenerationretina

    Embryonic stem cell trials for macular degeneration: a preliminary report

    Lancet (London, England)24 Jan 2012

Transplant rejection

no changein humans1

1 study

  1. Hesc-derived retinal pigment epithelium has no effect on transplant rejection in humans.

    “We did not identify signs of hyperproliferation, abnormal growth, or immune mediated transplant rejection in either patient during the first 4 months.”

    Human trialsubretinal transplantationretina4 monthsn = 2

    Embryonic stem cell trials for macular degeneration: a preliminary report

    Lancet (London, England)24 Jan 2012

Latest

Related